This article was originally published in abbreviated form at an Spanish on-line journal [http://www.siicsalud.com/dato/dat048/06406023a.htm]. The attached pdf link is the full version, not published previously. The article summarizes the issues related to phosphate retention, excess calcium absorption due to the use of calcium-containing phosphate binders and some of the data related to adverse cardiovascular consequences related to the exclusive use of such binders. This is followed by a discussion of calcium-free phosphate binders such as sevelamer and lanthanum carbonate. For more up-to-date information, the reader is encouraged to read some of the excellent recent reviews such as the one by Malindretos, published this month in Expert Opinion in Pharmacotherapy.
- Merck Provides Update on REVEAL Outcomes Study of Anacetrapib
- New drugs to treat anemia of chronic kidney disease
- FDA Endocrinologic and Metabolic Drugs Advisory Committee recommends approval of dapagliflozin for the treatment of type 2 diabetes in adults
- Combined ACE inhibition and angiotensin receptor blockade shows no advantage over single agent RAS inhibition in patients with diabetic nephropathy: VA-Nephron D study
- FDA Advisory Committee recommends against approval of Tolvaptan for polycystic kidney disease